comparemela.com

Latest Breaking News On - Oncology stock down - Page 7 : comparemela.com

Brokerages Set Rain Oncology Inc. (NASDAQ:RAIN) Price Target at $17.00

Shares of Rain Oncology Inc. (NASDAQ:RAIN – Free Report) have been assigned a consensus recommendation of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. Ten analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among […]

United-states
Roth-mkm
Kevinc-tang
Rain-oncology-inc
Morgan-stanley
Squarepoint-ops
Goldman-sachs-group-inc
Rain-oncology-company-profile
Nasdaq
Renaissance-technologies
Rain-oncology
Free-report

Tang Capital Management LLC Purchases Shares of 479,854 Elevation Oncology, Inc. (NASDAQ:ELEV)

Tang Capital Management LLC acquired a new stake in Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 479,854 shares of the company’s stock, valued at approximately $456,000. Tang Capital Management LLC […]

Nasdaq
Tang-capital-management
Elevation-oncology-inc
Blackrock-inc
Virtu-financial
Annandale-capital
Exchange-commission
Renaissance-technologies
Millennium-management
Elevation-oncology
Get-rating

Elevation Oncology (NASDAQ:ELEV) Upgraded at SVB Securities

SVB Securities upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a report issued on Tuesday, The Fly reports. SVB Securities currently has $8.00 target price on the stock, up from their previous target price of $5.00. Separately, Wedbush reiterated an outperform rating and set […]

United-states
Elevation-oncology-company-profile
Elevation-oncology-inc
Tang-capital-management
Sio-capital-management
Renaissance-technologies
Geode-capital-management
Elevation-oncology
Get-rating
Moderate-buy
Oncology-stock-down

Elevation Oncology (NASDAQ:ELEV) Upgraded at SVB Leerink

SVB Leerink upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a research report report published on Tuesday morning, PriceTargets.com reports. A number of other analysts have also recently issued reports on ELEV. Wedbush restated an outperform rating and set a $4.00 price objective on […]

United-states
Tang-capital-management
Elevation-oncology-inc
Sio-capital-management
Geode-capital-management
Renaissance-technologies
Elevation-oncology
Get-rating
Moderate-buy
Oncology-stock-down
Capital-management

Rain Oncology (NASDAQ:RAIN) Downgraded by Roth Capital to Neutral

Roth Capital lowered shares of Rain Oncology (NASDAQ:RAIN – Get Rating) from a buy rating to a neutral rating in a report published on Tuesday morning, PriceTargets.com reports. A number of other research analysts have also recently weighed in on the company. Oppenheimer cut Rain Oncology from an outperform rating to a market perform rating […]

United-states
Roth-mkm
Rain-therapeutics-inc
Securities-exchange-commission
Renaissance-technologies
Morgan-stanley
Squarepoint-ops
Rain-oncology-company-profile
Boxer-capital-llc
Goldman-sachs-group-inc
Roth-capital
Rain-oncology

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.